Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barré syndrome (GBS)

Regulatory information
Hansa Medical AB (publ) today announced data demonstrating that inactivation of IgG by IdeS treatment significantly promoted the recovery and reduced the degeneration of peripheral nerves in a model of the acute autoimmune disease Guillain-Barré syndrome (GBS).

The data were presented in an article entitled "IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndrome" by Dr. Yu-Zhong Wang and Dr. Nobuhiro Yuki. The article was published in the scientific journal Experimental Neurology (http://dx.doi.org/10.1016/j.expneurol.2017.02.010). 

Dr Christian Kjellman, Senior Vice President R&D at Hansa Medical AB said “The data covered by this publication demonstrate that our IdeS treatment could be a promising therapeutic strategy for the treatment of GBS. Potentially it could offer faster time to recovery, shorter stay in ICU/hospital and reduced risk of residual neurological deficits. We are making plans to begin a Phase II study in GBS."

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 16:00 CET on February 16, 2017.